JPH0622725A - Enteric metabolism improving food and enteric metabolism improver - Google Patents

Enteric metabolism improving food and enteric metabolism improver

Info

Publication number
JPH0622725A
JPH0622725A JP4144927A JP14492792A JPH0622725A JP H0622725 A JPH0622725 A JP H0622725A JP 4144927 A JP4144927 A JP 4144927A JP 14492792 A JP14492792 A JP 14492792A JP H0622725 A JPH0622725 A JP H0622725A
Authority
JP
Japan
Prior art keywords
chitosan
improver
foods
enteric
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP4144927A
Other languages
Japanese (ja)
Other versions
JP2978332B2 (en
Inventor
Koji Sakamoto
廣司 坂本
Emiko Ishioka
恵美子 石岡
Takashi Tsugita
隆志 次田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KATOKICHI BIO KK
Nippon Kayaku Co Ltd
Original Assignee
KATOKICHI BIO KK
Nippon Kayaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KATOKICHI BIO KK, Nippon Kayaku Co Ltd filed Critical KATOKICHI BIO KK
Priority to JP4144927A priority Critical patent/JP2978332B2/en
Publication of JPH0622725A publication Critical patent/JPH0622725A/en
Application granted granted Critical
Publication of JP2978332B2 publication Critical patent/JP2978332B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

PURPOSE:To obtain the improver containing chitosan as an active ingredient, having intestine controlling action and useful as a constipation improver, an agent for preventing abnormal fermentation of gastrointestine, an agent for reducing load to liver function, preventives for colon cancer, ulcerative colitis, etc. CONSTITUTION:The improver contains chitosan obtained by using carapace of crustacea, e.g. crab or prawn as a raw material and having 1.5-2.5 multi- dispersibility (weight average molecular weight/number average molecular weight) as an active ingredient. Furthermore, the enteric metabolism improving foods are obtained by adding 0.1-25W/W% of the improver based on total amount of foods to foods. Daily intake of chitosan is preferably 0.5-5g.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、キトサンを有効成分と
する腸内代謝改善食品及び腸内代謝改善剤に関する。
TECHNICAL FIELD The present invention relates to a food for improving intestinal metabolism and an agent for improving intestinal metabolism, which comprises chitosan as an active ingredient.

【0002】[0002]

【従来の技術】従来、腸内代謝改善剤としては、オリゴ
糖、ビフィズス菌や乳酸菌などの整腸作用を有するもの
が使用されてきた。また、腸内代謝改善食品としても同
様にオリゴ糖やビフィズス菌及び乳酸菌を含有する食品
が使用されている。
2. Description of the Related Art Conventionally, oligosaccharides, bifidobacteria, lactic acid bacteria, and the like having an intestinal regulating action have been used as agents for improving intestinal metabolism. Similarly, foods containing oligosaccharides, bifidobacteria and lactic acid bacteria are used as foods for improving intestinal metabolism.

【0003】一方、キチンは、カニ、エビ等の甲殻類の
殻や糸状菌、きのこ等の細胞壁、また、昆虫などに生体
の支持組織として含まれる直鎖のアミノ多糖であり、全
地球上で年間約1011tが生物生産されると推測されて
いる未利用有機資源として最大のものである。キトサン
は、キチンを脱アセチル化したもので、キチンが溶媒難
溶性であるのに対し、希酸に可溶となる。このキトサン
は天然物で唯一のカチオン性ポリマーであり、研究段階
ではその機能性について多方面で検討されているが、工
業的には、水処理用の凝集剤として市販されている以外
はほとんど利用されていなかった。最近になって、植物
活力増強剤、機能性食品、抗菌性の食品添加物等に使用
された例があるが、まだまだその用途は限られたもので
あり、キトサンが腸内代謝を改善することは知られてい
ない。
On the other hand, chitin is a linear aminopolysaccharide contained in shells of crustaceans such as crabs and shrimps, cell walls such as filamentous fungi, mushrooms, etc., and as a supporting tissue of living organisms in insects, etc. It is the largest unused organic resource that is estimated to produce about 10 11 tons per year. Chitosan is a deacetylated form of chitin, and although chitin is poorly soluble in a solvent, it becomes soluble in a dilute acid. This chitosan is the only cationic polymer in natural products, and its functionality has been studied in various fields at the research stage, but it is mostly used industrially except that it is commercially available as a flocculant for water treatment. Was not done. Recently, it has been used as a plant vitality enhancer, functional food, antibacterial food additive, etc., but its use is still limited, and chitosan improves intestinal metabolism. Is not known.

【0004】[0004]

【発明が解決しようとする課題】本発明はキトサンの新
規用途の開発を目的とする。
The present invention is directed to the development of new uses for chitosan.

【0005】[0005]

【課題を解決するための手段】本発明者らは種々検討し
た結果、キトサンが糞便中の腸内腐敗物質量を減少さ
せ、かつ、悪玉菌と言われる、クロストリジアのレシチ
ナーゼ(−)菌の腸内での増殖を特異的に押さえること
を見い出した。本発明は上記知見に基づいて完成された
ものである。即ち、本発明はキトサンを有効成分とする
腸内代謝改善食品及びキトサンを有効成分とする腸内代
謝改善剤に関する。
Means for Solving the Problems As a result of various investigations by the present inventors, chitosan reduces the amount of intestinal putrefactive substances in feces, and the intestine of Clostridia lecithinase (-), which is said to be a bad bacterium. It was found that the growth in the plant was specifically suppressed. The present invention has been completed based on the above findings. That is, the present invention relates to a food for improving intestinal metabolism containing chitosan as an active ingredient and an agent for improving intestinal metabolism containing chitosan as an active ingredient.

【0006】本発明における腸内代謝改善剤及び腸内代
謝改善食品とは、糞便中の腸内腐敗物質量を減少させ、
かつクロストリジア属のレシチナーゼ(−)菌の増殖を
特異的に押さえることのできるもののことである。
The intestinal metabolism-improving agent and the intestinal metabolism-improving food in the present invention are those which reduce the amount of intestinal putrefactive substances in feces,
In addition, the proliferation of lecithinase (-) bacteria of the genus Clostridia can be specifically suppressed.

【0007】腸内腐敗物質としては、肝硬変、高アンモ
ニア血症などの疾病に関与するアンモニア、硫化物(文
献:光岡知足、腸内細菌学 朝倉書店 東京(1990)P
187-191 )、大腸癌、潰瘍性大腸炎、肝腫瘍や皮膚癌の
プロモーターとされているインドール類、フェノール
類、クレゾール(文献:(1) 光岡知足、腸内細菌学 朝
倉書店 東京(1990)P289-290 ,P329 ,P366 ,
(2) 福島恒男他、日消外会誌 16(3) 552-556, 1983 )
などがあげられる。
As intestinal putrefactive substances, ammonia and sulfides involved in diseases such as cirrhosis and hyperammonemia (Reference: Michioka Tomohi, Enterobacteriaceae Asakura Shoten Tokyo (1990) P
187-191), colon cancer, ulcerative colitis, indoles, phenols, and cresols that are promoters of liver tumors and skin cancer (Reference: (1) Michioka Michioka, Enterobacteriaceae Asakura Shoten Tokyo (1990) P289-290, P329, P366,
(2) Tsuneo Fukushima et al., Japan-China Foreign Journal 16 (3) 552-556, 1983)
And so on.

【0008】本発明で使用されるキトサンは重量平均分
子量が約10〜100万、好ましくは約30〜70万の
ものである。ここで重量平均分子量はゲル濾過カラムを
用いた高速液体クロマトグラフィーにより定められる。
The chitosan used in the present invention has a weight average molecular weight of about 10 to 1,000,000, preferably about 300 to 700,000. Here, the weight average molecular weight is determined by high performance liquid chromatography using a gel filtration column.

【0009】測定条件 カラム;TSK ガードカラム+G6000PWXL +G3000PWX
L 移動相;0.4M 酢酸バッファー(pH4.0) 温 度;40℃ 流 速;0.6ml/min データ処理;島津C−R4A+GPCプログラム
[(株)島津製作所製] 標準物質;昭和電工製プルラン(分子量: 5,800〜2,46
0,000 ) 又、本発明で使用するキトサンの多分散度(重量平均分
子量/数平均分子量)は約1.5〜2.5が好ましい。
Measuring condition column; TSK guard column + G6000PWXL + G3000PWX
L mobile phase; 0.4 M acetate buffer (pH 4.0) temperature; 40 ° C. flow rate; 0.6 ml / min data processing; Shimadzu C-R4A + GPC program [Shimadzu Corporation] standard material; Showa Denko pullulan (Molecular weight: 5,800-2,46
The polydispersity (weight average molecular weight / number average molecular weight) of chitosan used in the present invention is preferably about 1.5 to 2.5.

【0010】又、その粘度は約10〜2000 cps、好ましく
は約30〜1000 cps(0.5%酢酸水溶液にキトサンを
0.5%濃度に溶解し、回転式B型粘度計により20℃
で測定した値)のものが好ましく、さらにその脱アセチ
ル化度は約75〜100%、好ましくは約80〜95%
(指示薬としてトルイジンブルー溶液を用い、 1/400
Nポリビニル硫酸カリウム溶液でPVSKコロイド滴定
法により測定した値)のものが好ましい。
The viscosity is about 10 to 2000 cps, preferably about 30 to 1000 cps (chitosan is dissolved in 0.5% acetic acid aqueous solution to a concentration of 0.5%, and the viscosity is 20 ° C. by a rotary B-type viscometer.
(Value measured in step 1), and the degree of deacetylation thereof is about 75 to 100%, preferably about 80 to 95%.
(Using toluidine blue solution as an indicator, 1/400
A value measured by a PVSK colloid titration method with N polyvinyl potassium sulfate solution) is preferable.

【0011】又、その粒度は50メッシュパス(タイラ
ー)、好ましくは80メッシュパスのものがよい。
The particle size is 50 mesh pass (Tyler), preferably 80 mesh pass.

【0012】本発明で使用するキトサンは、例えばカ
ニ、エビ、昆虫などの甲殻類の殻、きのこ、糸状菌等の
細胞壁、好ましくはカニ、エビ等の甲殻類の殻を原料と
し、例えば次の方法により製造される。
The chitosan used in the present invention is prepared by using, for example, the shell of crustaceans such as crab, shrimp and insect, the cell wall of mushrooms and filamentous fungi, and the shell of crustaceans such as crab and shrimp as raw materials. Manufactured by the method.

【0013】まず、原料を希アルカリ水溶液中で加熱し
てタンパク質を除去し、水洗した後、希酸水溶液中でカ
ルシウム分を除去すると同時に温度、時間等の条件を変
えて分子量をコントロールし、その後水洗してキチンを
得る。次に、キチンを濃アルカリ水溶液中で加熱して脱
アセチル化した後、水洗してキトサンを得る。
First, the raw material is heated in a dilute alkaline aqueous solution to remove proteins and washed with water, and then the calcium content is removed in a dilute acidic aqueous solution, and at the same time, the conditions such as temperature and time are changed to control the molecular weight. Wash with water to obtain chitin. Next, chitin is heated in a concentrated alkaline aqueous solution for deacetylation and then washed with water to obtain chitosan.

【0014】本発明においてキトサンは、ビスケット、
クッキー、キャンデー、ゼリー、スープ、麺類、畜肉製
品、惣菜、パン、ケーキ、乳製品、アイスクリーム、天
ぷら粉、パン粉、味噌、清涼飲料、果汁入飲料、乳飲
料、その他あらゆる飲食物に添加して摂取してもよく、
また、そのまま粉剤、錠剤、カプセル剤、顆粒剤等の製
剤として経口的に服用してもよい。
In the present invention, chitosan is a biscuit,
Cookies, candy, jellies, soups, noodles, meat products, side dishes, breads, cakes, dairy products, ice cream, tempura powder, bread crumbs, miso, soft drinks, juice-containing beverages, dairy drinks, and all other foods and drinks May be taken,
Alternatively, it may be orally taken as it is as a preparation such as a powder, tablet, capsule, granule and the like.

【0015】キトサンの摂取量は1日当り0.1〜10
g、好ましくは0.5〜5g程度がよい。キトサンを食
品に添加する場合、その添加量は食品全量に対し0.0
1〜50 w/w%、好ましくは0.1〜25 w/w%程度が
よい。又、製剤中のキトサンの割合は0.1〜100 w
/w%である。
The intake of chitosan is 0.1-10 per day.
g, preferably about 0.5 to 5 g. When chitosan is added to food, the amount added is 0.0 with respect to the total amount of food.
1 to 50 w / w%, preferably 0.1 to 25 w / w%. The ratio of chitosan in the preparation is 0.1-100 w
/ w%.

【0016】[0016]

【実施例】【Example】

<実験方法>表1に示すような組成のキトサン配合ビス
ケットを調製し、以下の試験に使用した。健康な男性
(年齢21〜22才)8人に、試験前の対照期として表
1に示す組成からキトサンを除いたキトサン無添加ビス
ケット(重量10g/枚)を3枚/日の割合で1週間摂
取させ、試験期はキトサン配合ビスケットをキトサンと
して3g/日の割合で1週間投与後、6g/日の割合で
1週間投与した。更に、試験後の対照期としてキトサン
無添加ビスケットを3枚/日の割合で1週間摂取させ
た。試験前の対照期の末日、試験開始後1および2週間
目、試験後の対照期の末日に糞便を採取し、糞便中のア
ンモニア、硫化物、フェノール、エチルフェノール、ク
レゾール、インドール、スカトールを下記の条件で測定
した他、主な腸内細菌数、糞便重量、糞便のpH、糞便
の水分も計測した。それぞれの測定方法を次に示す。
<Experimental method> Chitosan-containing biscuits having the composition shown in Table 1 were prepared and used in the following tests. Eight healthy men (aged 21 to 22) were given a chitosan-free biscuit (weight: 10 g / sheet) obtained by removing chitosan from the composition shown in Table 1 as a control period before the test at a rate of 3 sheets / day for 1 week. During the test period, the biscuit containing chitosan was administered as chitosan at a rate of 3 g / day for 1 week, and then at a rate of 6 g / day for 1 week. Furthermore, as a control period after the test, the chitosan-free biscuits were ingested at a rate of 3 sheets / day for 1 week. Feces were collected on the last day of the control period before the test, 1 and 2 weeks after the start of the test, and on the last day of the control period after the test, and ammonia, sulfide, phenol, ethylphenol, cresol, indole, and skatole in the feces were described below. In addition to the measurement under the above conditions, the number of main intestinal bacteria, the weight of feces, the pH of feces, and the water content of feces were also measured. Each measuring method is shown below.

【0017】糞便中の水分;糞便を常法によって凍結乾
燥し、前後の重量差から求めた。
Moisture in feces: Feces were freeze-dried by a conventional method and determined from the weight difference before and after.

【0018】糞便のpH;pHメーターにフラット型複
合電極を装着し、電極を直接糞便に差し込み測定した。
PH of feces: A flat type composite electrode was attached to a pH meter, and the electrodes were directly inserted into the feces for measurement.

【0019】アンモニア;隔膜型電極法により測定し
た。
Ammonia: Measured by the diaphragm electrode method.

【0020】インドール;Yoshihara らの方法で測定し
た(文献;I. Yoshihara and K. Murata Agric. Biol.
Chem., 41, 2083-2085 1977, I. Yoshihara Agric. Bio
l. Chem., 42, 1607-1609 1978, I. Yoshihara Agric.
Biol. Chem., 43, 1985-19871979)。
Indole; measured by the method of Yoshihara et al. (Reference; I. Yoshihara and K. Murata Agric. Biol.
Chem., 41, 2083-2085 1977, I. Yoshihara Agric. Bio
l. Chem., 42, 1607-1609 1978, I. Yoshihara Agric.
Biol. Chem., 43, 1985-19871979).

【0021】スカトール;同上 パラクレゾール;同上 フェノール;同上 硫化物;イオン電極法により測定した。Skatol; ibid Paracresol; ibid. Phenol; ibid. Sulfide; measured by the ion electrode method.

【0022】エチルフェノール;同上 なお、使用したキトサンは、重量平均分子量約58万、
多分散度1.95、粘度105 cps、脱アセチル化度8
5.2%、粒度は50メッシュパスのものである。
Ethylphenol; Same as above The chitosan used had a weight average molecular weight of about 580,000,
Polydispersity 1.95, viscosity 105 cps, deacetylation degree 8
The particle size is 5.2% and the particle size is 50 mesh pass.

【0023】[0023]

【表1】 キトサン含有ビスケット配合割合(%) 小麦粉 45.4 全 卵 2.8 マーガリン 17.0 粉 乳 1.7 砂 糖 11.3 膨張剤 0.5 還元麦芽糖水飴 11.3 キトサン 10.0 <結 果>表2に各種腸内腐敗物質及び糞便重量、糞便
のpH、糞便の水分を測定した結果を、表3に各種細菌
の排出状況を示す。全てのデータは平均値で表した。な
お、表中アンモニアの値は水分を含んだ糞便1g当たり
のmg数で、硫化物からスカトールまでの値は、水分を
含んだ糞便1g当たりのμg数である。
[Table 1] Blending ratio of chitosan-containing biscuits (%) Wheat flour 45.4 Whole egg 2.8 Margarine 17.0 Powder milk 1.7 Sand sugar 11.3 Swelling agent 0.5 Reduced maltose starch syrup 11.3 Chitosan 10.0 <Results> Table 2 shows the results of measuring various intestinal putrefactive substances, the weight of feces, the pH of feces, and the water content of feces, and Table 3 shows the excretion status of various bacteria. All data are expressed as average values. In the table, the value of ammonia is mg per 1 g of stool containing water, and the value from sulfide to skatole is the number of μg per 1 g of stool containing water.

【0024】[0024]

【表2】 物 質 投与前 投与1週間 投与2週間 投与後 アンモニア(mg/g) 261.3 125.4 106.2 232.1 硫化物(μg/g) 4.9 3.6 3.6 3.9 フェノール(〃) 31.8 12.9 15.5 21.7 エチルフェノール(〃) 9.6 1.6 2.5 5.6 パラクレゾール(〃) 61.9 19.6 24.8 51.6 インドール(〃) 54.3 16.2 22.3 38.1スカトール(〃) 20.5 9.1 7.5 19.2 糞便重量(g) 95.5 111.2 116.3 97.1 糞便のpH 6.4 6.2 6.3 6.5糞便水分(%) 74.9 76.7 76.4 74.6 [Table 2] Material Before administration 1 week after administration 2 weeks after administration Ammonia (mg / g) 261.3 125.4 106.2 232.1 Sulfide (μg / g) 4.9 3.6 3.6 3.6 3.9 Phenol (〃) 31.8 12.9 15.5 21.7 Ethylphenol (〃) 9.6 1.6 2.5 2.5 5.6 Paracresol (〃) 61.9 19.6 24.8 51.6 Indole (〃) 54.3 16.2 22.3 38.1 Skatole (〃) 20.5 9.1 7.5 19.2 Fecal weight (g) 95.5 111.2 116.3 97.1 Fecal pH 6.4 6.2 6.3 6.3 6.5 Fecal moisture (%) 74.9 76.7 76.4 74.6

【0025】[0025]

【表3】 微生物名 投与前 投与1週間 投与2週間 投与後 Bifidobacteria 8/8 8/8 8/8 8/8 Bacteroidaceae 8/8 8/8 8/8 8/8 Eubacteria 8/8 8/8 8/8 8/8 Peptococcaceae 8/8 8/8 8/8 8/8 Megasphaerae 7/8 3/8 4/8 7/8 Curved rods 6/8 3/8 3/8 4/8Clostridia Lecithinase-positive 7/8 8/8 8/8 8/8 Lecithinase-negative* 8/8 4/8 4/8 7/8 Lactobacilli 8/8 8/8 8/8 8/8 Enterobacteriaceae 8/8 8/8 8/8 8/8 Pseudomonas 6/8 6/8 7/8 7/8 Streptococci 8/8 8/8 8/8 8/8 Staphylococci 7/8 7/8 7/8 4/8 Bacilli 6/8 5/8 6/8 2/8 Yeasts 4/8 2/8 1/8 5/8 Molds 1/8 0/8 0/8 0/8Veillonellae 4/8 4/8 4/8 2/8 注) 表中の数字は菌排出人数/被験者数を意味する。[Table 3] Microorganism name Before administration 1 week after administration 2 weeks after administration Bifidobacteria 8/8 8/8 8/8 8/8 Bacteroidaceae 8/8 8/8 8/8 8/8 Eubacteria 8/8 8/8 8/8 8 / 8 Peptococcaceae 8/8 8/8 8/8 8/8 Megasphaerae 7/8 3/8 4/8 7/8 Curved rods 6/8 3/8 3/8 4/8 Clostridia Lecithinase-positive 7/8 8 / 8 8/8 8/8 Lecithinase-negative * 8/8 4/8 4/8 7/8 Lactobacilli 8/8 8/8 8/8 8/8 Enterobacteriaceae 8/8 8/8 8/8 8/8 Pseudomonas 6/8 6/8 7/8 7/8 Streptococci 8/8 8/8 8/8 8/8 Staphylococci 7/8 7/8 7/8 4/8 Bacilli 6/8 5/8 6/8 2 / 8 Yeasts 4/8 2/8 1/8 5/8 Molds 1/8 0/8 0/8 0/8 Veillonellae 4/8 4/8 4/8 2/8 Note) The numbers mean the number of bacteria discharged / the number of subjects.

【0026】表2から明らかなように、キトサンを投与
することにより、各種腸内腐敗物質を減少させることが
できる。又、表3から明らかなように特に悪玉菌と言わ
れるクロストリジア属のレシチナーゼ(−)菌の排出人
数が投与前に比し半分に減少しており、該菌の増殖を押
さえていることがわかる。このことは、キトサンが悪玉
菌の増殖を押さえることにより腸内フローラの改善に寄
与していることを意味している。
As is clear from Table 2, various intestinal putrefactive substances can be reduced by administering chitosan. Further, as is clear from Table 3, the number of excreted lecithinase (-) bacteria of the genus Clostridia, which are said to be particularly bad bacteria, is reduced by half compared to before administration, and it can be seen that the growth of the bacteria is suppressed. . This means that chitosan contributes to the improvement of intestinal flora by suppressing the growth of bad bacteria.

【0027】従って、本発明の腸内代謝改善剤および腸
内代謝改善食品は整腸作用を有し、便秘改善剤、胃腸の
異常醗酵防止剤、肝機能に対する負荷の軽減剤、大腸
癌、潰瘍性大腸炎の予防剤および糞便臭の軽減剤として
の用途等が期待される。
Therefore, the intestinal metabolism-improving agent and the intestinal metabolism-improving food of the present invention have an intestinal regulating action, and are a constipation-improving agent, a gastrointestinal abnormal fermentation inhibitor, a load reducing agent for liver function, colon cancer, and ulcer. It is expected to be used as a preventive agent for inflammatory bowel disease and as a faecal odor reducing agent.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 C08B 37/08 A 7329−4C // A21D 2/18 ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 5 Identification code Office reference number FI technical display location C08B 37/08 A 7329-4C // A21D 2/18

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】 キトサンを有効成分とすることを特徴と
する腸内代謝改善食品。
1. A food for improving intestinal metabolism, which comprises chitosan as an active ingredient.
【請求項2】 キトサンを有効成分とすることを特徴と
する腸内代謝改善剤。
2. An intestinal metabolism-improving agent, which comprises chitosan as an active ingredient.
JP4144927A 1992-05-11 1992-05-11 Intestinal metabolism improving food and intestinal metabolism improving agent Expired - Fee Related JP2978332B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4144927A JP2978332B2 (en) 1992-05-11 1992-05-11 Intestinal metabolism improving food and intestinal metabolism improving agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4144927A JP2978332B2 (en) 1992-05-11 1992-05-11 Intestinal metabolism improving food and intestinal metabolism improving agent

Publications (2)

Publication Number Publication Date
JPH0622725A true JPH0622725A (en) 1994-02-01
JP2978332B2 JP2978332B2 (en) 1999-11-15

Family

ID=15373452

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4144927A Expired - Fee Related JP2978332B2 (en) 1992-05-11 1992-05-11 Intestinal metabolism improving food and intestinal metabolism improving agent

Country Status (1)

Country Link
JP (1) JP2978332B2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07327633A (en) * 1994-06-02 1995-12-19 Matsura:Kk Chitosan processed food
US5711476A (en) * 1995-09-11 1998-01-27 The Procter & Gamble Company Carton for granular materials
JP2000281583A (en) * 1999-03-26 2000-10-10 Gotoo Corporation:Kk Health auxiliary preparation containing leaf of mulberry and health auxiliary beverage and food
KR20010044175A (en) * 1999-12-24 2001-06-05 장태순 Method for inhibiting synthesis and secretion of cell activating substances using chitosan and Food composition comprising chitosan for the inhibition
WO2004084919A1 (en) * 2003-03-26 2004-10-07 Cheiron Japan Co. Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood
US6890913B2 (en) 2003-02-26 2005-05-10 Food Industry Research And Development Institute Chitosans
WO2013038776A1 (en) * 2011-09-15 2013-03-21 国立大学法人鳥取大学 Therapeutic agent for inflammatory bowel disease
JP2016166237A (en) * 2011-04-15 2016-09-15 マリン ポリマー テクノロジーズ,インコーポレーテッド Treatment of disease with poly-n-acetylglucosamine nanofibers

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07327633A (en) * 1994-06-02 1995-12-19 Matsura:Kk Chitosan processed food
US5711476A (en) * 1995-09-11 1998-01-27 The Procter & Gamble Company Carton for granular materials
JP2000281583A (en) * 1999-03-26 2000-10-10 Gotoo Corporation:Kk Health auxiliary preparation containing leaf of mulberry and health auxiliary beverage and food
KR20010044175A (en) * 1999-12-24 2001-06-05 장태순 Method for inhibiting synthesis and secretion of cell activating substances using chitosan and Food composition comprising chitosan for the inhibition
US6890913B2 (en) 2003-02-26 2005-05-10 Food Industry Research And Development Institute Chitosans
WO2004084919A1 (en) * 2003-03-26 2004-10-07 Cheiron Japan Co. Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood
CN100372541C (en) * 2003-03-26 2008-03-05 康利隆日本公司 Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood
EP1616570A4 (en) * 2003-03-26 2009-08-12 Cheiron Japan Co Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood
JP2016166237A (en) * 2011-04-15 2016-09-15 マリン ポリマー テクノロジーズ,インコーポレーテッド Treatment of disease with poly-n-acetylglucosamine nanofibers
WO2013038776A1 (en) * 2011-09-15 2013-03-21 国立大学法人鳥取大学 Therapeutic agent for inflammatory bowel disease
JP5496427B2 (en) * 2011-09-15 2014-05-21 国立大学法人鳥取大学 Inflammatory bowel disease treatment
JPWO2013038776A1 (en) * 2011-09-15 2015-03-23 国立大学法人鳥取大学 Inflammatory bowel disease treatment

Also Published As

Publication number Publication date
JP2978332B2 (en) 1999-11-15

Similar Documents

Publication Publication Date Title
RU2376889C2 (en) Food product and beverage modulating human indestinal flora, food additives, its production and methods and usage methods of arabinoxylan preparations
RU2314114C2 (en) Gel fraction prepared from flea plantain seed husk
JP4194839B2 (en) Method for producing pectin hydrolyzate
EP2323669B2 (en) Arabinoxylan for modulating the barrier function of the intestinal surface
JP3020387B2 (en) Antiviral substance
US8461130B2 (en) Food containing glycogen and use thereof
US20020155126A1 (en) Pharmacological composition containing yeast cell wall fraction
JP2014037422A (en) Use of water-soluble cellulose derivative for prevention or treatment of metabolic syndrome
JP4615812B2 (en) Composition containing peptide and electrolyte excretion promoting substance and food containing the same
JP2978332B2 (en) Intestinal metabolism improving food and intestinal metabolism improving agent
WO2004110174A1 (en) Composition and foods for lowering glycemic index
JPH0987302A (en) Composition containing chitosan
JP2007217435A (en) Agent for prevention and/or amelioration of constipation composed of yeast cell wall fraction
JP4830130B2 (en) Chitosan combination composition and food
JP2005046054A (en) Diet food and pharmaceutical preparation for diet
JPH0586227A (en) Water-soluble dietary fiber complex and food composition containing the same
JPH05238945A (en) Intestinal environment-improving agent
JP3719478B2 (en) Diet food
JPH03175951A (en) Insoluble edible fiber and same fiber-containing food
JPH06247860A (en) Iron absorption promoter comprising decomposition product of guar gum with enzyme as active ingredient
JPWO2009031603A1 (en) Fat absorption inhibiting composition
JP2632577B2 (en) Hyperuricemia improving agent and food for improvement
WO2022075222A1 (en) Growth promoter for intestinal bacteria, blood glucose lowering agent, serum cholesterol lowering agent, and food or beverage composition containing same
JPH0654665A (en) Hdl cholesterol-enriched food and enriching agent
JP3993907B2 (en) Calcium absorption promoter

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees
R154 Certificate of patent or utility model (reissue)

Free format text: JAPANESE INTERMEDIATE CODE: R154